Id |
Subject |
Object |
Predicate |
Lexical cue |
T211 |
0-6 |
Sentence |
denotes |
4.2.1. |
T212 |
7-31 |
Sentence |
denotes |
C4-O-Acetyl Modification |
T213 |
32-146 |
Sentence |
denotes |
For example, in the horse, C4-O-acetyl modification of Neu5Ac (SA) occupies more than 50% of the total SA content. |
T214 |
147-221 |
Sentence |
denotes |
The C4-O-acetylated Neu5Ac, Neu4,5Ac2, inhibits the influenza A2 virus HA. |
T215 |
222-359 |
Sentence |
denotes |
De-acetylation reagents such as NaOH or NaIO4 treatment completely hemagglutinate Neu4,5Ac2 by elimination of the C4-O-acetyl group [33]. |
T216 |
360-497 |
Sentence |
denotes |
The C4-O-acetyl Neu5Ac species are found in various sources such as equine erythrocyte GM3, starfish A. rubens and fish [34,35,36,37,38]. |
T217 |
498-583 |
Sentence |
denotes |
C4-O-acetylated Neu5Ac facilitates the initial attachment of viruses to target cells. |
T218 |
584-753 |
Sentence |
denotes |
Like the influenza C virus, infectious salmon anemia virus (ISAV), a member of the Orthomyxoviridae family, contains HE and HEF proteins to mediate virus entry and exit. |
T219 |
754-907 |
Sentence |
denotes |
C4-O-Ac Neu5Ac is the major receptor determinant of ISAV in receptor binding and destruction [38], while the influenza C virus recognizes C9-O-Ac Neu5Ac. |
T220 |
908-1099 |
Sentence |
denotes |
The acetylesterase RDE of ISAV cleaves C4-O-Ac via 4-SA-O-acetylesterase with a short turnover time, whereas C9-O-Ac Neu5Ac is cleaved by 9-SA-O-acetylesterase with a long turnover time [34]. |
T221 |
1100-1239 |
Sentence |
denotes |
The position of SA O-acetylation is linked to functions including substrate differentiation of enzymes such as NAs and esterase by C4 O-Ac. |
T222 |
1240-1369 |
Sentence |
denotes |
Previous development of O-Ac site-selective NA inhibitors were based on the conceptual consideration of different O-Ac positions. |
T223 |
1370-1478 |
Sentence |
denotes |
The O-Ac of SAs is site-specific, as C4 of Neu5Ac is considered to be a potential position for modification. |
T224 |
1479-1587 |
Sentence |
denotes |
Historically, inhibitors of influenza A and B viruses-sialidases were designed by Von-Itzstein in 1993 [39]. |
T225 |
1588-1697 |
Sentence |
denotes |
The Ac group-based C4 substitution interacts with amino acid Glu-119 present in the active site of sialidase. |
T226 |
1698-1867 |
Sentence |
denotes |
Guanidine-attached C4 of C2–C3 unsaturated SA (Neu5Ac2en) inhibits activity of sialidases isolated from influenza A virus (Singapore/1/57) and B virus (Victoria/102/85). |
T227 |
1868-2002 |
Sentence |
denotes |
The same scenario was applied for sialidase inhibition of the human parainfluenza virus type 3, which has HN and fusion proteins [40]. |
T228 |
2003-2081 |
Sentence |
denotes |
The C4 of Neu5Ac2en was substituted by alkyl groups such as the O-ethyl group. |
T229 |
2082-2171 |
Sentence |
denotes |
For example, Zanamivir has a substitution with a 4-guanidino group with an IC50 of 25 μM. |
T230 |
2172-2245 |
Sentence |
denotes |
Thus, sialidase inhibition is important for C4 modification of Neu5Ac2en. |
T231 |
2246-2389 |
Sentence |
denotes |
Later, oseltamivir with the tradename Tamiflu (Basel, Switzerland) and zanamivir with the tradename Relenza (London, UK) were established [41]. |
T232 |
2390-2463 |
Sentence |
denotes |
These drugs exhibit some adverse side effects that restrict clinical use. |